Spinout raises £5 million for MND treatment

University spinout company Crucible Therapeutics has secured £5 million from Northern Gritstone and Argobio Studio to develop novel therapies for MND and frontotemporal dementia.

The funding will pay for essential development and manufacturing work, taking the company up to its first clinical trial – laying the groundwork to treat some of the common forms of MND and FTD.

Crucible’s Director, Professor Guillaume Hautbergue, said:

What an incredible journey!  I feel blessed and honoured to be working with them and moving forward a bench discovery onto the translational path. I am now delighted to continue our preclinical development programme in partnership with Argobio Studio and Northern Gritstone who bring significant levels of expertise and support.